



16 August 2023

## **ASX ANNOUNCEMENT**

### **Conference Call with ImpediMed Directors**

ImpediMed Limited (**ImpediMed** or the **Company**) (ASX:IPD) advises that its Directors will be holding a shareholder conference call at 9:30am AEST (Sydney/Melbourne) on Thursday, 17 August 2023.

The live call and Q&A will be hosted by ImpediMed's Chair, Don Williams and will be joined by the Board of Directors as well as CEO, Rick Valencia and CFO, Tim Cruickshank.

**To pre-register, please follow this link:**

[https://us02web.zoom.us/webinar/register/WN\\_e8qK3KzgSlqpcv9gOQdNNA](https://us02web.zoom.us/webinar/register/WN_e8qK3KzgSlqpcv9gOQdNNA)

Investors are encouraged to send questions in advance to Hannah Howlett at [hhowlett@we-worldwide.com](mailto:hhowlett@we-worldwide.com).

**Approved for release by the Managing Director and CEO, Mr Rick Valencia.**

### **Contact Details**

#### **Investor relations Contact:**

Hannah Howlett

WE Communications

T: +61 (0) 4 5064 8064

E: [investorrelations@impedimed.com](mailto:investorrelations@impedimed.com)

### **About ImpediMed**

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health. ImpediMed produces the SOZO® Digital Health Platform, which is FDA-cleared, CE-marked, and ARTG-listed for multiple indications, including lymphoedema, heart failure, and protein calorie malnutrition and sold in select markets globally.

In March 2023, the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for Survivorship were updated and reference bioimpedance spectroscopy as the recommended objective tool to screen at-risk cancer patients for early signs of lymphoedema. With the SOZO Digital Health Platform and L-Dex®, ImpediMed is the only company to offer FDA-cleared technology that uses bioimpedance spectroscopy for the clinical assessment of lymphoedema. The connected digital health platform and large, attractive cancer-related lymphoedema market present an opportunity for continued strong growth through ImpediMed's SaaS subscription-based business.

For more information, visit [www.impedimed.com](http://www.impedimed.com).